Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Yamazaki, Tomoko ^a   Mori, Mayumi ^a   Arai, Satoko ^a   Tateishi, Ryosuke ^b   Abe, Masanori ^c   Ban, Mihoko ^d   Nishijima, Akemi ^a   Maeda, Maki ^d   Asano, Takeharu ^e   Kai, Toshihiro ^a,k   Izumino, Kiyohiro ^d   Takahashi, Jun ^d   Aoyama, Kayo ^a   Harada, Sei ^f   Takebayashi, Toru ^f   Gunji, Toshiaki ^g   Ohnishi, Shin ^h   Seto, Shinji ^d   Yoshida, Yukio ^e   Hiasa, Yoichi ^c   Koike, Kazuhiko ^b   Yamamura, Ken Ichi ⁱ   Inoue, Ken Ichiro ^d   Miyazaki, Toru ^a,j   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Inoue Hospital   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f KEIO UNIVERSITY   (Japan)

^g Kanto Teishin Hospital   (Japan)

^h NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

ⁱ KUMAMOTO UNIVERSITY   (Japan)

^j JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^k DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR OF MACROPHAGE PROTEIN; CARBON TETRACHLORIDE; LIVER PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS INHIBITOR OF MACROPHAGE PROTEIN, HUMAN; SCAVENGER RECEPTOR; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; BODY MASS; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FAT MASS; FEMALE; HEPATITIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; OBESITY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; VERY ELDERLY; WAIST CIRCUMFERENCE; WILD TYPE; YOUNG ADULT; ANIMAL; BLOOD; LIVER; LIVER TUMOR; PATHOLOGY;

ADULT; AGED; ANIMALS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MIDDLE AGED; RECEPTORS, SCAVENGER; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84907853293     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109123     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Bosch FX, Ribes J, Cleries R, Diaz M (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211.
3. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
4. Baffy G, Brunt EM, Caldwell SH (2012) Hepatocellular carcinoma in nonalcoholic fatty liver disease: an emerging menace. J Hepatol 56: 1384-91.
5. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231.
6. Hytiroglou P, Park YN, Krinsky G, Theise ND (2007) Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin North Am 36: 867-887, vii.
7. He G, Karin M (2011) NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 21: 159-168.
8. Park EJ, Lee JH, Yu GY, He G, Ali SR, et al. (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140: 197-208.
9. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, et al. (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11: 74-80.
10. Day CP, Saksena S (2002) Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 17: S377-S384.
11. Harrison SA, Torgerson S, Hayashi PH (2003) The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98: 2042-2047.
12. Torres DM, Harrison SA (2012) Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 32: 30-38.
13. Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51: 1820-1832.
14. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, et al. (2009) Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 44: 1190-1194.
15. Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, et al. (2009) Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res 42: 958-962.
16. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, et al. (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128: 2436-2443.
17. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, et al. (2009) Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49: 851-859.
18. Takuma Y, Nouso K (2010) Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 16: 1436-1441.
19. Miyazaki T, Hirokami Y, Matsuhashi N, Takatsuka H, Naito M (1999) Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J Exp Med 189: 413-422.
20. Arai S, Shelton JM, Chen M, Bradley MN, Castrillo A, et al. (2005) A role of the apoptosis inhibitory factor AIM/Sp a/Api6 in atherosclerosis development. Cell Metab 1: 201-213.
21. Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, et al. (2004) LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119: 299-309.
22. Valledor AF, Hsu LC, Ogawa S, Sawka-Verhelle D, Karin M, et al. (2004) Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci USA 101: 17813-17818.
23. Arai S, Maehara N, Iwamura Y, Honda S, Nakashima K, et al. (2013) Obesity-associated autoantibody production requires AIM to retain IgM immune complex on follicular dendritic cells. Cell Rep 3: 1187-1198.
24. Tissot JD, Sanchez JC, Vuadens F, Scherl A, Schifferli JA, et al. (2002) IgM are associated to Sp alpha (CD5 antigen-like). Electrophoresis 23: 1203-1206.
25. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N (2007) Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 53: 1792-1799.
26. Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, et al. (2009) A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer 9: 271.
27. Kim WK, Hwang HR, Kim do H, Lee PY, In YJ, et al. (2008) Glycoproteomic analysis of plasma from patients with atopic dermatitis: CD5L and ApoE as potential biomarkers. Exp Mol Med 40: 677-685.
28. Mera K, Uto H, Mawatari S, Ido A, Yoshimine Y, et al. (2014) Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C. BMC Gastroenterol 13: 14-27.
29. Kurokawa J, Arai S, Nakashima K, Nishijima A, Miyake K, et al. (2010) AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity. Cell Metab 11: 479-492.
30. Iwamura Y, Mori M, Nakashima K, Mikami T, Murayama K, et al. (2012) Apoptosis inhibitor of macrophage (AIM) diminishes lipid droplet-coating proteins leading to lipolysis in adipocytes. Biochem Biophys Res Commun 422: 476-481.
31. Arai S, Miyazaki T (2014) Impacts of the apoptosis inhibitor of macrophage (AIM) on obesity-associated inflammatory diseases. Semin Immunopathol 36: 3-12.
32. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, et al. (1996) New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int hepatol commun 6: 112-119.
33. Bryzgalova G, Lundholm L, Portwood N, Gustafsson J-A, Khan A, et al. (2008) Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen in high-fat diet-fed mice. Am J Physiol Endocrinol Metab 295: E904-E912.
34. Gao H, Bryzgalova G, Hedman E, Khan A, Efendic S, et al. (2006) Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: a possible mechanism is through direct regulation of signal transducer and activator of transcription 3. Mol Endocrinol 20: 1287-1299.
35. Han SI, Komatsu Y, Murayama A, Steffensen KR, Nakagawa Y, et al. (2014) Estrogen receptor ligands ameliorate fatty liver through a nonclassical estrogen receptor/Liver X receptor pathway in mice. Hepatology 59: 1791-1802.
36. Lundholm L, Movérare S, Steffensen KR, Nilsson M, Otsuki M, et al. (2004) Gene expression profiling identifies liver X receptor alpha as an estrogenregulated gene in mouse adipose tissue. J Mol Endocrinol 32: 879-892.
37. Tiano JP, Mauvais-Jarvis F (2012) Molecular mechanisms of estrogen receptors' suppression of lipogenesis in pancreatic b-cells. Endocrinology 153: 2997-3005.
38. Hage FG, Oparil S (2013) Ovarian hormones and vascular disease. Curr Opin Cardiol 28: 411-416.
39. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, et al. (2000) A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933-941.
40. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, et al. (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 49-57.
41. Wang H, Liu Y, Zhu L, Wang W, Wan Z, et al. (2014) 17β-estradiol promotes cholesterol efflux from vascular smooth muscle cells through a liver X receptor α-dependent pathway. Int J Mol Med 33: 550-558.
42. Hamada M, Nakamura M, Tran MT, Moriguchi T, Hong C, et al. (2014) MafB promotes atherosclerosis by inhibiting foam-cell apoptosis. Nat Commun 5: 3147.
43. Miyazaki T, Kurokawa J, Arai S (2011) AIMing at Metabolic Syndrome: Towards the development of novel therapies for metabolic diseases via apoptosis inhibitor of macrophage (AIM). Cir J 75: 2522-2531.
44. Xu Y, Fan H, Li X, Sun L, Hou Y (2012) 17β-Estradiol enhances response of mice spleen B cells elicited by TLR9 agonist. Cell Immunol 278: 125-135.
45. Li X, Xu Y, Ma L, Sun L, Fu G, et al. (2009) 17beta-estradiol enhances the response of plasmacytoid dendritic cell to CpG. PLoS One 4: e8412.
46. Bazin H, Malet F (1969) The metabolism of different immunoglobulin classes in irradiated mice. Immunology 17: 345-365.
47. Vieira P, Rajewsky K (1988) The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 18: 313-316.
48. Kai T, Yamazaki T, Arai S, Miyazaki T (2014) Stabilization and augmentation of circulating AIM in mice by synthesized IgM-Fc. PLoS One 9: e97037.